Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
3.07% $6.72
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 698.30 mill |
EPS: | -2.42 |
P/E: | -2.78 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 103.91 mill |
Avg Daily Volume: | 2.23 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.78 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.47x |
Company: PE -2.78 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.432 (-93.58%) $-6.29 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 6.02 - 7.42 ( +/- 10.45%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-16 | Fairmount Funds Management Llc | Buy | 1 166 666 | Common Stock |
2024-02-16 | Fairmount Funds Management Llc | Buy | 1 500 | Series B Convertible Preferred Stock |
2024-01-23 | Robinson John Edward | Buy | 300 000 | Stock Option (Right to Buy) |
2024-01-23 | Kearns Evan | Buy | 255 000 | Stock Option (Right to Buy) |
2024-01-23 | Sachs Jessica | Buy | 300 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 19 240 363 | Sell: 1 265 393 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.72 (3.07% ) |
Volume | 2.07 mill |
Avg. Vol. | 2.23 mill |
% of Avg. Vol | 93.07 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $6.32 | N/A | Active |
---|
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.